Please login to the form below

Cytokinetics

This page shows the latest Cytokinetics news and features for those working in and with pharma, biotech and healthcare.

Roche reshuffles its executive committee, again

Prior to joining Genetech Sabry was chief executive officer for start-up biotech and was founder and chief executive of biopharma Cytokinetics.

Latest news

Amgen agrees to take Cytokinetics' heart failure drug into phase III

originator, Cytokinetics, which has been waiting for the big biotech to make a decision for several weeks. ... Cytokinetics said recently that meetings have been held with both the FDA and EMA to discuss the design of the outcomes study, which is due to
Biogen buys into Ionis' nusinersen after positive phase III trial

Potential blockbuster spinal muscular atrophy drug will be filed “in the coming months” 
Roche buys rare disease firm Trophos in €470m deal

SMA therapy in development at Cytokinetics, while Biogen Idec and Isis Pharmaceuticals are also developing ISIS-SMNRx for the disease, a drug due to enter phase III soon.
Astellas forges $675m muscle alliance with Cytokinetics

Astellas has signed a major expansion of its collaboration with US biotech Cytokinetics to include neuromuscular diseases. ... It works in a similar way to Cytokinetics' tirasemtiv which is already in phase II trials for amyotrophic lateral sclerosis (ALS
Amgen drug misses endpoint in acute heart failure trial

A drug in development by Amgen and Cytokinetics to treat symptoms of heart failure has missed its primary endpoint in a phase II trial.

More from news
Approximately 4 fully matching, plus 4 partially matching documents found.

Latest Intelligence

Deal Watch February 2017

Sale of Priority Review Voucher (PRV). 125. Cytokinetics/ Royalty Pharma. 4.5% royalty on global sales of omecamtiv mecarbil for heart failure (phase III).
Deal Watch July 2016

Real Relationships. Astellas and Cytokinetics have announced another extension to their agreement involving the development of their skeletal muscle activators, tirasemtiv and CK-2127107. ... 181. Cytokinetics/ Astellas. Tirasemtiv, CK-2127107 and
Astellas: Ten years young

option, while in muscle disease Astellas is working with Californian clinical-stage biopharmaceutical company Cytokinetics, looking at mechanisms for improving muscle strength.
Heart failure therapy embarks on a new era

In collaboration with Cytokinetics, Amgen is developing omecamtiv mecarbil, an activator of cardiac myosin that is designed to increase the duration of cardiac muscle contractility and improve cardiac muscle performance.
Deal Watch table for December 2014

Licence. 700. Cytokinetics / Astellas Pharma. CK-2127107, fast skeletal troponin activator, in Spinal Muscular Atrophy and other neuromuscular indications (p1).

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Associate Scientific Director: Salary TBC

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Account Manager: Negotiable

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Sudler London - Senior Medical Writer: Competitive

Senior Writer, Healthcare Advertising, London: Excellent package

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Graduate Scientific Editor: DOE

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Senior Training Manager - Surrey: Competitive Salary &Bonus

Senior Account Manager – Healthcare Advertising: Salary TBC

Medical Writers Required - Hertfordshire: Competitive

Account Manager- 4 days per week or full-time: Salary TBC

Account Director, Healthcare Advertising Agency: Salary TBC

Senior Medical Writer, MedComms Agency: Salary TBC

Account Director or Senior Account Director: Salary TBC

Systematic Review Lead- London: Negotiable

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Subscribe to our email news alerts

PMHub

Add my company

Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....